Corcept Therapeutics (CORT) Competitors

Corcept Therapeutics (NASDAQ:CORT) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

Does the media refer more to CORT or RPRX?

In the previous week, Corcept Therapeutics had 1 more articles in the media than Royalty Pharma. MarketBeat recorded 18 mentions for Corcept Therapeutics and 17 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.26 beat Corcept Therapeutics' score of 0.91 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	10 Very Positive mention(s)	5 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CORT or RPRX?

Corcept Therapeutics presently has a consensus price target of $138.25, suggesting a potential upside of 90.30%. Royalty Pharma has a consensus price target of $47.33, suggesting a potential upside of 30.31%. Given Corcept Therapeutics' higher possible upside, equities analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Is CORT or RPRX more profitable?

Royalty Pharma has a net margin of 48.23% compared to Corcept Therapeutics' net margin of 19.33%. Royalty Pharma's return on equity of 24.71% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	19.33%	20.40%	16.64%
Royalty Pharma	48.23%	24.71%	13.87%

Which has more risk and volatility, CORT or RPRX?

Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

Which has higher valuation & earnings, CORT or RPRX?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$675.04M	11.41	$141.21M	$1.16	62.63
Royalty Pharma	$2.26B	9.02	$858.98M	$1.85	19.64

Do institutionals and insiders have more ownership in CORT or RPRX?

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Royalty Pharma beats Corcept Therapeutics on 9 of the 17 factors compared between the two stocks.